GentiBio
GentiBio is a biotech company focused on developing engineered T regulatory cell therapies for various immune and inflammatory diseases, with its lead product GNTI-122 targeting type 1 diabetes.
Company Overview
GentiBio specializes in developing engineered T regulatory (Treg) cell therapies aimed at treating autoimmune, auto-inflammatory, alloimmune, and allergic diseases. The company employs a modular engineering platform to create optimized Treg phenotypes tailored for specific disease conditions. By addressing challenges in Treg therapeutics, such as scalable engineering, tissue targeting, and IL-2 signaling support, GentiBio aims to offer transformative therapeutic solutions.
Lead Candidate: GNTI-122
GentiBio's lead candidate, GNTI-122, is an autologous engineered Treg product designed explicitly for the treatment of type 1 diabetes. GNTI-122 exemplifies the company's innovative approach to leveraging Treg cells for specific autoimmune conditions. This product is part of GentiBio's broader effort to develop customized Treg cells tailored to meet the specific needs of various diseases.
Modular Engineering Platform
GentiBio utilizes a modular engineering platform to generate optimized Treg phenotypes. The platform is designed to address key challenges in Treg therapeutics, including scalable engineering, tissue targeting, and IL-2 signaling support. This approach allows GentiBio to fine-tune Treg cells to specific disease environments and improve therapeutic efficacy.
Funding and Financial Backing
GentiBio has successfully raised significant funds to advance its mission. The company secured $157 million in Series A financing to propel the development of engineered regulatory T cells. Additionally, GentiBio was launched with $20 million in seed funding, supported by prominent investors including OrbiMed, Novartis Venture Fund, and RA Capital Management.
Collaborations and Partnerships
GentiBio is collaborating with Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases. This partnership underscores GentiBio's commitment to leveraging strategic collaborations to expand the therapeutic scope and application of its engineered Treg products.